Patients with a large prostate show a higher prevalence of androgenetic alopecia

Wen Chieh Chen, Chao-Chun Yang, Guan Yu Chen, Meng Chie Wu, Hamm Ming Sheu, Tzong Shin Tzai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH) are both androgen-dependent disorders, displaying in situ high levels of dihydrotestosterone with a good therapeutic response to finasteride. Embryological development of both the hair follicle and the prostate depends on mesenchymal-epithelial interaction, which is influenced by the expression of type 2 5α-reductase. The aim of this study was to elucidate the association between the size of the prostate gland and the prevalence and severity of AGA. A total of 46 patients age between 56 and 87 years were retrospectively recruited. They fulfilling the clinical diagnosis of BPH defined as (1) prostate volume > 30 cm3, measured by transrectal ultrasound, (2) maximal urine flow rate < 15 ml/s and mean urine flow rate < 10 ml/s, and (3) prostate serum albumin < 10 ng/ml. The control group comprised 34 patients aged between 49 and 81 years with urogenital infection, cystitis or urolithiasis. The expression and severity of AGA were evaluated by dermatologists using modified Norwood/Hamilton classification. Patients with a prostate volume > 30 cm3 had a higher prevalence of AGA than patients with a smaller prostate (< 30 cm3) (83.3% vs 61.3%; P < 0.05). The prostate size, however, did not correlate with the severity of AGA in either group or in the whole patient group. The prevalence of AGA was not significantly different in patients with or without BPH (85.7% vs 70.6%). The prostate was slightly larger among patients with AGA than among those without AGA (mean ± SD 42.7 ± 17.4 vs 35.4 ± 14.9 cm3), but this was not statistically significant. There was no significant correlation between the age of onset of AGA and the development of BPH. Our results suggest that a larger prostate is associated with a higher prevalence of AGA. It remains to be seen if long-term use of finasteride in AGA patients will prophylactically lower the incidence of BPH.

Original languageEnglish
Pages (from-to)245-249
Number of pages5
JournalArchives of Dermatological Research
Volume296
Issue number6
DOIs
Publication statusPublished - 2004 Jan 1

Fingerprint

Alopecia
Prostate
Prostatic Hyperplasia
Finasteride
Hair Follicle
Dihydrotestosterone
Age of Onset
Androgens
Oxidoreductases
Urine

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Chen, Wen Chieh ; Yang, Chao-Chun ; Chen, Guan Yu ; Wu, Meng Chie ; Sheu, Hamm Ming ; Tzai, Tzong Shin. / Patients with a large prostate show a higher prevalence of androgenetic alopecia. In: Archives of Dermatological Research. 2004 ; Vol. 296, No. 6. pp. 245-249.
@article{d1f36af9e763418db6578229305af182,
title = "Patients with a large prostate show a higher prevalence of androgenetic alopecia",
abstract = "Androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH) are both androgen-dependent disorders, displaying in situ high levels of dihydrotestosterone with a good therapeutic response to finasteride. Embryological development of both the hair follicle and the prostate depends on mesenchymal-epithelial interaction, which is influenced by the expression of type 2 5α-reductase. The aim of this study was to elucidate the association between the size of the prostate gland and the prevalence and severity of AGA. A total of 46 patients age between 56 and 87 years were retrospectively recruited. They fulfilling the clinical diagnosis of BPH defined as (1) prostate volume > 30 cm3, measured by transrectal ultrasound, (2) maximal urine flow rate < 15 ml/s and mean urine flow rate < 10 ml/s, and (3) prostate serum albumin < 10 ng/ml. The control group comprised 34 patients aged between 49 and 81 years with urogenital infection, cystitis or urolithiasis. The expression and severity of AGA were evaluated by dermatologists using modified Norwood/Hamilton classification. Patients with a prostate volume > 30 cm3 had a higher prevalence of AGA than patients with a smaller prostate (< 30 cm3) (83.3{\%} vs 61.3{\%}; P < 0.05). The prostate size, however, did not correlate with the severity of AGA in either group or in the whole patient group. The prevalence of AGA was not significantly different in patients with or without BPH (85.7{\%} vs 70.6{\%}). The prostate was slightly larger among patients with AGA than among those without AGA (mean ± SD 42.7 ± 17.4 vs 35.4 ± 14.9 cm3), but this was not statistically significant. There was no significant correlation between the age of onset of AGA and the development of BPH. Our results suggest that a larger prostate is associated with a higher prevalence of AGA. It remains to be seen if long-term use of finasteride in AGA patients will prophylactically lower the incidence of BPH.",
author = "Chen, {Wen Chieh} and Chao-Chun Yang and Chen, {Guan Yu} and Wu, {Meng Chie} and Sheu, {Hamm Ming} and Tzai, {Tzong Shin}",
year = "2004",
month = "1",
day = "1",
doi = "10.1007/s00403-004-0514-z",
language = "English",
volume = "296",
pages = "245--249",
journal = "Archives of Dermatological Research",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "6",

}

Patients with a large prostate show a higher prevalence of androgenetic alopecia. / Chen, Wen Chieh; Yang, Chao-Chun; Chen, Guan Yu; Wu, Meng Chie; Sheu, Hamm Ming; Tzai, Tzong Shin.

In: Archives of Dermatological Research, Vol. 296, No. 6, 01.01.2004, p. 245-249.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patients with a large prostate show a higher prevalence of androgenetic alopecia

AU - Chen, Wen Chieh

AU - Yang, Chao-Chun

AU - Chen, Guan Yu

AU - Wu, Meng Chie

AU - Sheu, Hamm Ming

AU - Tzai, Tzong Shin

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH) are both androgen-dependent disorders, displaying in situ high levels of dihydrotestosterone with a good therapeutic response to finasteride. Embryological development of both the hair follicle and the prostate depends on mesenchymal-epithelial interaction, which is influenced by the expression of type 2 5α-reductase. The aim of this study was to elucidate the association between the size of the prostate gland and the prevalence and severity of AGA. A total of 46 patients age between 56 and 87 years were retrospectively recruited. They fulfilling the clinical diagnosis of BPH defined as (1) prostate volume > 30 cm3, measured by transrectal ultrasound, (2) maximal urine flow rate < 15 ml/s and mean urine flow rate < 10 ml/s, and (3) prostate serum albumin < 10 ng/ml. The control group comprised 34 patients aged between 49 and 81 years with urogenital infection, cystitis or urolithiasis. The expression and severity of AGA were evaluated by dermatologists using modified Norwood/Hamilton classification. Patients with a prostate volume > 30 cm3 had a higher prevalence of AGA than patients with a smaller prostate (< 30 cm3) (83.3% vs 61.3%; P < 0.05). The prostate size, however, did not correlate with the severity of AGA in either group or in the whole patient group. The prevalence of AGA was not significantly different in patients with or without BPH (85.7% vs 70.6%). The prostate was slightly larger among patients with AGA than among those without AGA (mean ± SD 42.7 ± 17.4 vs 35.4 ± 14.9 cm3), but this was not statistically significant. There was no significant correlation between the age of onset of AGA and the development of BPH. Our results suggest that a larger prostate is associated with a higher prevalence of AGA. It remains to be seen if long-term use of finasteride in AGA patients will prophylactically lower the incidence of BPH.

AB - Androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH) are both androgen-dependent disorders, displaying in situ high levels of dihydrotestosterone with a good therapeutic response to finasteride. Embryological development of both the hair follicle and the prostate depends on mesenchymal-epithelial interaction, which is influenced by the expression of type 2 5α-reductase. The aim of this study was to elucidate the association between the size of the prostate gland and the prevalence and severity of AGA. A total of 46 patients age between 56 and 87 years were retrospectively recruited. They fulfilling the clinical diagnosis of BPH defined as (1) prostate volume > 30 cm3, measured by transrectal ultrasound, (2) maximal urine flow rate < 15 ml/s and mean urine flow rate < 10 ml/s, and (3) prostate serum albumin < 10 ng/ml. The control group comprised 34 patients aged between 49 and 81 years with urogenital infection, cystitis or urolithiasis. The expression and severity of AGA were evaluated by dermatologists using modified Norwood/Hamilton classification. Patients with a prostate volume > 30 cm3 had a higher prevalence of AGA than patients with a smaller prostate (< 30 cm3) (83.3% vs 61.3%; P < 0.05). The prostate size, however, did not correlate with the severity of AGA in either group or in the whole patient group. The prevalence of AGA was not significantly different in patients with or without BPH (85.7% vs 70.6%). The prostate was slightly larger among patients with AGA than among those without AGA (mean ± SD 42.7 ± 17.4 vs 35.4 ± 14.9 cm3), but this was not statistically significant. There was no significant correlation between the age of onset of AGA and the development of BPH. Our results suggest that a larger prostate is associated with a higher prevalence of AGA. It remains to be seen if long-term use of finasteride in AGA patients will prophylactically lower the incidence of BPH.

UR - http://www.scopus.com/inward/record.url?scp=11244269805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244269805&partnerID=8YFLogxK

U2 - 10.1007/s00403-004-0514-z

DO - 10.1007/s00403-004-0514-z

M3 - Article

VL - 296

SP - 245

EP - 249

JO - Archives of Dermatological Research

JF - Archives of Dermatological Research

SN - 0340-3696

IS - 6

ER -